日本接种奥密克戎XBB.1.5单价疫苗后的细胞免疫与体液免疫及IgG亚类分布
日本25名医务人员接种第7剂奥密克戎XBB.1.5单价疫苗,按近期新冠感染史分为血清阴性18人和血清阳性7人,分析中和抗体、RBD IgG、IgG亚类及T细胞应答。接种后针对XBB.1.5和BA.2.86的中和抗体显著升高,尤以血清阳性者为著;总RBD IgG无显著变化,IgG亚类无显著转换,两组T细胞应答相当。部分接种前IgG滴度低者接种后抗体未升高,作者提出对潜在免疫耐受的担忧。
要点
- 接种XBB.1.5单价疫苗后针对XBB.1.5和BA.2.86的中和抗体显著升高,血清阳性者尤为明显。
- 总RBD IgG水平无显著变化,IgG亚类无显著转换,提示抗体靶向RBD以外区域。
- 血清阳性与血清阴性组T细胞应答相当;部分接种前IgG滴度低者接种后抗体未升高。
核心结论
- XBB.1.5疫苗接种增强针对奥密克戎变异株的体液免疫,且无显著IgG亚类转换,但部分接种前IgG滴度低者接种后抗体未升高,作者提出对潜在免疫耐受的担忧。
研究设计与样本
- 研究纳入25名XBB.1.5疫苗接种者,按近期新冠感染史分为血清阴性18人和血清阳性7人,检测针对奥密克戎亚变异株的中和抗体滴度、受体结合域(RBD)IgG水平、IgG亚类分布及T细胞应答。
主要发现
- 接种XBB.1.5疫苗后,针对XBB.1.5和BA.2.86变异株的中和抗体滴度显著升高,尤其在血清阳性个体中。
- 接种后总RBD IgG水平无显著变化,提示XBB.1.5疫苗有效诱导针对RBD以外区域的抗体。
- IgG亚类分析显示接种后无显著亚类转换。
- 针对病毒的T细胞应答在血清阳性组与血清阴性组间相当。
- 部分接种前IgG滴度低的个体接种后抗体水平未升高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Up to seven doses of coronavirus disease 2019 (COVID-19) mRNA vaccines (BNT162b2) were administered to Japanese healthcare workers, until February 2024. The monovalent Omicron XBB.1.5 vaccine (hereafter called XBB.1.5 vaccine) was used for dose 7. OBJECTIVE: Although the XBB.1.5 vaccine has been reported to induce a robust increase in neutralizing antibodies against the currently circulating Omicron variant BA.2.86, little is known about its serological effects in Japan, where the BNT162b2 mRNA vaccine is the most frequently administered in the world. STUDY DESIGN: Twenty-five recipients of the XBB.1.5 vaccine, categorized as seronegative (n = 18) or seropositive (n = 7) based on their recent history of COVID-19, were analyzed. Neutralizing antibody titers against Omicron subvariants, receptor binding domain (RBD) IgG levels, IgG subclass distribution, and T-cell responses were assessed. RESULTS: We found a significant increase in neutralizing antibody titers against XBB.1.5 and BA.2.86 variants following XBB.1.5 vaccination, particularly in seropositive individuals. No significant change in total RBD IgG levels was observed, indicating efficient induction of antibodies targeting regions outside the RBD by XBB.1.5 vaccination. IgG subclass analysis demonstrated no significant subclass switching after vaccination. T-cell responses against the virus were comparable between seropositive and seronegative groups. CONCLUSIONS: The study suggests that XBB.1.5 vaccination enhances humoral immunity against Omicron variants without significant IgG subclass switching. However, some individuals with low pre-vaccination IgG titers did not exhibit increased antibody levels post-vaccination, raising concerns about potential immune tolerance.
引用
- Sano K, Kurosawa T, Horikawa K, et al. Cellular and humoral immunity and IgG subclass distribution after omicron XBB.1.5 monovalent vaccination in Japan. Vaccine. 2024. PMID: 39418690. doi:10.1016/j.vaccine.2024.126452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。